CAPRICOR THERAPEUTICS INC (CAPR) Fundamental Analysis & Valuation

NASDAQ:CAPR • US14070B3096

Current stock price

35.27 USD
+1.41 (+4.16%)
At close:
35.1 USD
-0.17 (-0.48%)
After Hours:

This CAPR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CAPR Profitability Analysis

1.1 Basic Checks

  • In the past year CAPR has reported negative net income.
  • CAPR had a negative operating cash flow in the past year.
  • In the past 5 years CAPR always reported negative net income.
  • In the past 5 years CAPR reported 4 times negative operating cash flow.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • CAPR's Return On Assets of -29.51% is fine compared to the rest of the industry. CAPR outperforms 66.67% of its industry peers.
  • Looking at the Return On Equity, with a value of -34.35%, CAPR is in the better half of the industry, outperforming 71.51% of the companies in the same industry.
Industry RankSector Rank
ROA -29.51%
ROE -34.35%
ROIC N/A
ROA(3y)-30.4%
ROA(5y)-39.51%
ROE(3y)-53.59%
ROE(5y)-94.15%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CAPR Health Analysis

2.1 Basic Checks

  • CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CAPR has more shares outstanding
  • Compared to 5 years ago, CAPR has more shares outstanding
  • The debt/assets ratio for CAPR has been reduced compared to a year ago.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 22.19 indicates that CAPR is not in any danger for bankruptcy at the moment.
  • CAPR's Altman-Z score of 22.19 is amongst the best of the industry. CAPR outperforms 88.76% of its industry peers.
  • There is no outstanding debt for CAPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.19
ROIC/WACCN/A
WACC9.54%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • CAPR has a Current Ratio of 9.01. This indicates that CAPR is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CAPR (9.01) is better than 75.78% of its industry peers.
  • CAPR has a Quick Ratio of 9.01. This indicates that CAPR is financially healthy and has no problem in meeting its short term obligations.
  • CAPR's Quick ratio of 9.01 is fine compared to the rest of the industry. CAPR outperforms 75.78% of its industry peers.
Industry RankSector Rank
Current Ratio 9.01
Quick Ratio 9.01
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CAPR Growth Analysis

3.1 Past

  • CAPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.33%.
  • The Revenue for CAPR has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-88.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-287.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.13% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 301.91% on average over the next years. This is a very strong growth
EPS Next Y104.81%
EPS Next 2Y40.41%
EPS Next 3Y38.13%
EPS Next 5Y40.13%
Revenue Next Year19640.8%
Revenue Next 2Y1328.07%
Revenue Next 3Y687.91%
Revenue Next 5Y301.91%

3.3 Evolution

CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 -10 15

More info and screens

Find the best growth stocksShow best growing peers

2

4. CAPR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CAPR. In the last year negative earnings were reported.
  • CAPR is valuated quite expensively with a Price/Forward Earnings ratio of 324.16.
  • CAPR's Price/Forward Earnings ratio is rather cheap when compared to the industry. CAPR is cheaper than 87.79% of the companies in the same industry.
  • CAPR is valuated expensively when we compare the Price/Forward Earnings ratio to 22.24, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 324.16
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CAPR does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as CAPR's earnings are expected to grow with 38.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.41%
EPS Next 3Y38.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CAPR Dividend Analysis

5.1 Amount

  • CAPR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAPR Fundamentals: All Metrics, Ratios and Statistics

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (4/24/2026, 8:24:55 PM)

After market: 35.1 -0.17 (-0.48%)

35.27

+1.41 (+4.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners54.07%
Inst Owner Change0.05%
Ins Owners0.93%
Ins Owner Change0.02%
Market Cap2.04B
Revenue(TTM)N/A
Net Income(TTM)-105.04M
Analysts83.75
Price Target54.98 (55.88%)
Short Float %19.82%
Short Ratio7.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.63%
Min EPS beat(2)-12.56%
Max EPS beat(2)3.3%
EPS beat(4)1
Avg EPS beat(4)-23.13%
Min EPS beat(4)-64.08%
Max EPS beat(4)3.3%
EPS beat(8)3
Avg EPS beat(8)-27.58%
EPS beat(12)7
Avg EPS beat(12)-8.59%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.1%
PT rev (3m)6.1%
EPS NQ rev (1m)-1.81%
EPS NQ rev (3m)-3.68%
EPS NY rev (1m)106.92%
EPS NY rev (3m)106.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)8.43%
Revenue NY rev (3m)18.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 324.16
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.67
P/tB 6.67
EV/EBITDA N/A
EPS(TTM)-2.26
EYN/A
EPS(NY)0.11
Fwd EY0.31%
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0
BVpS5.29
TBVpS5.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -29.51%
ROE -34.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.4%
ROA(5y)-39.51%
ROE(3y)-53.59%
ROE(5y)-94.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 620.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.01
Quick Ratio 9.01
Altman-Z 22.19
F-Score3
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)306.73%
Cap/Depr(5y)406.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-287.5%
EPS Next Y104.81%
EPS Next 2Y40.41%
EPS Next 3Y38.13%
EPS Next 5Y40.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year19640.8%
Revenue Next 2Y1328.07%
Revenue Next 3Y687.91%
Revenue Next 5Y301.91%
EBIT growth 1Y-154.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-96.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.55%
OCF growth 3YN/A
OCF growth 5YN/A

CAPRICOR THERAPEUTICS INC / CAPR Fundamental Analysis FAQ

What is the fundamental rating for CAPR stock?

ChartMill assigns a fundamental rating of 4 / 10 to CAPR.


What is the valuation status for CAPR stock?

ChartMill assigns a valuation rating of 2 / 10 to CAPRICOR THERAPEUTICS INC (CAPR). This can be considered as Overvalued.


How profitable is CAPRICOR THERAPEUTICS INC (CAPR) stock?

CAPRICOR THERAPEUTICS INC (CAPR) has a profitability rating of 1 / 10.


What is the financial health of CAPRICOR THERAPEUTICS INC (CAPR) stock?

The financial health rating of CAPRICOR THERAPEUTICS INC (CAPR) is 8 / 10.